Estimation of the Incidence of Guillain-Barré Syndrome During Pregnancy in the United States
- PMID: 31312665
- PMCID: PMC6419988
- DOI: 10.1093/ofid/ofz071
Estimation of the Incidence of Guillain-Barré Syndrome During Pregnancy in the United States
Abstract
Guillain-Barré syndrome (GBS) is an adverse event of interest after vaccination, yet few data are available for background rates during pregnancy. We confirmed 2 cases of incident GBS and estimated an incidence of 2.8 confirmed GBS cases per million person-years (95% confidence interval, 0.5-9.3), indicating rare occurrence. Our findings will help inform safety assessments of Zika vaccines in pregnant populations.
Keywords: Guillain-Barré syndrome; Vaccine Safety Datalink; pregnancy.
References
-
- Durbin A, Wilder-Smith A. An update on Zika vaccine developments. Expert Rev Vaccines 2017; 16:781–7. - PubMed
-
- Shui IM, Rett MD, Weintraub E, et al. Guillain-Barré syndrome incidence in a large United States cohort (2000–2009). Neuroepidemiology 2012; 39:109–15. - PubMed
-
- Klein NP, Ray P, Carpenter D, et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 2010; 28:1062–8. - PubMed
-
- Cheng Q, Jiang GX, Fredrikson S, et al. Increased incidence of Guillain-Barré syndrome postpartum. Epidemiology 1998; 9:601–4. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
